Cristal Therapeutics Proprietary CriPec Nanomedicine Platform and Promising Preclinical Data Highlighted in Three Recent Publications
Cristal Therapeutics, has announced the publication of three articles on CriPec-based nanomedicines in Nano Today, Journal of Controlled Release and Biomaterials. The publications are co-authored by Dr Cristianne Rijcken, founder and CSO of Cristal Therapeutics, and clearly demonstrate the superior therapeutic performance of CriPec nanomedicines in preclinical models, as well as the position of the CriPec platform in the overall nanotherapeutics field.
In the first publication by Talleli et al. in Nano Today, Dr Rijcken provides her vision on the translational development of polymeric nanoparticles. Many different micelles have been developed in recent years, and some of them have steadily progressed into clinical evaluation. Increasing evidence suggests that for efficient drug targeting, the micelles need to be stabilised, to prevent premature disintegration. Particularly upon temporarily covalently entrapment of drugs within these nanoparticles (i.e., the CriPec platform), promising efficacy in various animal models has been demonstrated. Recent advances in this field, including tailorable drug release kinetics at the target site as well as potential applications and the clinical development path are described.
The second publication of Hu et al., on CriPec docetaxel (the lead candicate of Cristal Therapeutics in Biomaterials) describes the complete regression of breast tumour with a single dose of docetaxel-entrapped core-cross-linked polymeric micelles.
CriPec docetaxel is a nanoparticle with covalently entrapped docetaxel, designed to have a long blood circulation profile and significantly enhanced tumour accumulation, followed by locally more extended exposure as a result of sustained release of docetaxel over time. In tumour bearing mice, CriPec docetaxel accumulated at least 20 times more in tumour tissue compared to an equivalent dose of the commercially available docetaxel (Taxotere). A superior survival benefit was demonstrated in tumour xenografts and even complete regression has been achieved upon a single administration of CriPec docetaxel. These remarkable antitumour effects are attributed to the enhanced tumour accumulation and anti-stromal activity. In addition, the preclinical data showed that CriPec docetaxel exhibited superior tolerability as compared to Taxotere.
In the third publication of Hu et al., in the Journal of Controlled Release article, Dr Rijcken and colleagues demonstrated the applicability of the CriPec platform for peptides and the ability to achieve therapeutically relevant blood levels for more than one week upon only a single intravenous injection to rats. Meanwhile, CriPec has also been successfully combined with larger peptides (>30 amino acids).
The transiently stable entrapment of peptides in CriPec nanoparticles prevents burst release and undesired peak levels, protects peptides against degradation, and enables sustained systemic levels. In addition, since the pharmacokinetic profile of a CriPec nanoparticle is not dependent on the entrapped compound, these CriPec peptide products are also expected to display superior tumour tissue targeting.
"These findings clearly demonstrate the added value of the CriPec platform, being the improved therapeutic index in oncology for various drug molecules. Relative to the worldwide developments in nanomedicine, the CriPec platform is really state-of-the-art and capable of translating the biological requirements into a fully tuneable nanomedicine with superior therapeutic outcome." said Prof. Dr Twan Lammers, head of the Department of Nanomedicine and Theranostics at RWTH Aachen University Clinic (Germany).
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance